LTI
2.8.2022 11:02:08 CEST | Business Wire | Press release
Larsen & Toubro Infotech (BSE: 540005, NSE: LTI ), a global technology consulting and digital solutions company, has announced the expansion of its collaboration with Microsoft to focus on developing high-value cloud solutions for enterprises. As a part of this multi-year collaboration, LTI has launched a dedicated Microsoft business unit that develops and offers end-to-end digital transformation solutions.
Through this association, LTI will also train 12,000 professionals from its existing workforce on various Microsoft technologies by 2024. The main objective of this effort is to enable skill development of LTI employees that are a part of the Microsoft unit and enhance their competencies across technologies like cloud, data, IoT and security.
Nachiket Deshpande, Chief Operating Officer, LTI, said, “LTI has a long-standing relationship with Microsoft as a strategic partner, service provider, and customer. Our reaffirmed partnership with Microsoft will enable us to innovate and offer 170+ distinct services to our joint customers. Additionally, we will also focus on the training and upskilling of our talent pool that is a part of the dedicated Microsoft business unit, to empower them to meet changing business and market requirements.”
Siddharth Bohra, Chief Business Officer & Head of Cloud Business Unit, LTI , said, “Enterprises across the globe are increasingly embracing cloud, and LTI has made impressive strides in developing a multi-dimensional capability on Azure to meet this demand. As part of this collaboration, LTI and Microsoft will jointly innovate, develop, and sell solutions to assist enterprises in acceleration of their digital transformation journeys.”
Julie Sanford, Vice President, Partner GTM, Programs & Experiences, Microsoft , said, “Through their new Microsoft Business Unit, LTI will be able to help customers implement cloud strategies and drive business transformation across industries and geographies. We look forward to working with LTI as they build new capabilities and deliver innovative solutions on the Microsoft Cloud.”
Through this association, LTI will attain the Solution Partner designation across all the Microsoft Solution Areas. LTI also has the following advanced specializations on Azure:
- SAP on Azure : Validating the capability of implementing SAP solutions on Azure.
- Analytics on Azure : Demonstrating the expertise in delivering analytics solutions in Microsoft Azure.
- Windows Server and SQL Server : Expertise in migrating production workloads to Microsoft Azure.
- Modernization of Web Applications : Validating expertise in migrating and deploying production web application workloads, applying DevOps, and managing app services in Microsoft Azure.
- Kubernetes on Azure : validating capabilities in deploying and managing production workloads in the cloud using containers and managing hosted Kubernetes environments in Azure.
- Low Code Application Development : Expertise in building solutions using Power Apps.
- The Data Warehouse Migration to Microsoft Azure : Validating expertise in analyzing existing workloads and performing ETL operations to migrate data to cloud-based data warehouses.
- Cloud Security : Validates a means for your company to showcase capabilities to implement comprehensive security solutions across Azure, hybrid, and multi-cloud environments.
- Threat Protection : provides a means for your company to showcase proven, verifiable expertise in deploying Microsoft Threat Protection or Microsoft Cloud App Security workloads.
- AI and Machine Learning in Microsoft Azure : Validates capabilities on enabling customer adoption of Al and implementing Azure solutions for Al-powered apps.
LTI is an Azure Expert MSP Partner which demonstrates deep knowledge, extensive experience, and proven success in implementing specialized workloads such as Migration and Modernization, SAP on Azure, Data Analytics, Internet of things (IoT), Security, and Microsoft Dynamics 365.
About LTI:
LTI (NSE: LTI ) is a global technology consulting and digital solutions Company helping more than 495 clients succeed in a converging world. With operations in 33 countries, we go the extra mile for our clients and accelerate their digital transformation journeys. Founded in 1997 as a subsidiary of Larsen & Toubro Limited, our unique heritage gives us unrivalled real-world expertise to solve the most complex challenges of enterprises across all industries. Each day, our team of more than 46,000 LTItes enable our clients to improve the effectiveness of their business and technology operations and deliver value to their customers, employees, and shareholders. Find more at https://www.lntinfotech.com or follow us at @LTI_Global .
Connect with LTI:
Read More:
- LTI Becomes Microsoft Azure Expert Managed Services Provider
- LTI has Earned the Kubernetes on Microsoft Azure Advanced Specialization
View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005516/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom